European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines
Date: September 25, 2023
The EMA has opened a public consultation on a reflection paper presenting views on artificial intelligence and machine learning at any step of the lifecycle of human and veterinary medicines, from drug discovery to the post-authorisation setting.
All interested stakeholders are invited to comment on the draft reflection paper and to identify opportunities and risks of AI in the field of medicines – deadline: 31 December 2023
The topic will be further discussed during a joint HMA/EMA workshop scheduled for 20-21 November 2023.
The feedback from stakeholders will be analysed and considered for the finalisation of the reflection paper and future development of guidance as relevant.
Find out more here.
Explore More News
Newsletter Committee: Meet Marta
The ACDM is delighted to welcome Marta Kowalska of CluePoints to the Newsletter . . .
Read More
AI model trained on de-identified data from 57 million people
Researchers at UCL have trained an AI model using de-identified data from 57 million . . .
Read More
ACDM Regulatory Considerations DMEG Update: ICH E6 (R3) GCP Final Publication Released
The final publication of ICH E6 (R3) Good Clinical Practice (GCP) General Principles and . . .
Read More
ICH E6(R3) Guideline reaches Step 4 of the ICH Process
ICH E6(R3) reaches Step 4 of the ICH Process on 6th January 2025.
The guideline . . .
Read More
U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties
The U.S. Food and Drug Administration has issued its first guidance on the use of . . .
Read More
ACDM DMEG News: Regulatory Updates and Forthcoming Challenges for 2025
As 2024 draws to a close, the Regulatory Considerations Data Management Expert Group . . .
Read More
Audit Trail Review DMEG Update – New Guide
The Audit Trail Review (ATR) DMEG has been hard at work putting the finishing touches on a . . .
Read More
Risk Based Quality Management DMEG Update – Recent Discussions
This year our focus has switched away from generalised RBQM to applying risk-based . . .
Read More
Regulatory Considerations DMEG Update – September 2024
The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .
Read More
Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)
This article has been submitted by Leeni Joshua of ICON plc
Introduction:
Digital Data . . .
Read More
Guidance for Industry: Conducting Clinical Trials With Decentralized Elements
The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .
Read More
Welcome FGK Clinical Research as a new corporate member
The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .
Read More
